Yahoo
NasdaqCM - Nasdaq Real Time Price USD

Bolt Biotherapeutics, Inc. (BOLT)

6.54 +0.16 (+2.51%)
At close: November 6 at 4:00:01 PM EST
Chart Range Bar
Loading chart for BOLT
  • Previous Close 6.38
  • Open 6.40
  • Bid 6.30 x 100
  • Ask 7.97 x 200
  • Day's Range 6.30 - 6.55
  • 52 Week Range 3.10 - 7.78
  • Volume 136,537
  • Avg. Volume 250,356
  • Market Cap (intraday) 15.415M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -16.51
  • Earnings Date (est.) --
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est --
  • Zacks Rating Neutral

Bolt Biotherapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company offers product candidates and platform technologies, including PRA-216, BDC-4182, a Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; the Boltbody Immune-Stimulating Antibody Conjugate (ISAC) platform, and the INSPIRE platform. It serves patients, clinical investigators, and biopharmaceutical partners. The company is based in Redwood City, California.

www.boltbio.com

--

Full Time Employees

--

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/6/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

BOLT
19.60%
S&P 500 (^GSPC)
7.76%

1-Year Return

BOLT
36.82%
S&P 500 (^GSPC)
9.77%

3-Year Return

BOLT
67.30%
S&P 500 (^GSPC)
68.96%

5-Year Return

BOLT
97.25%
S&P 500 (^GSPC)
57.04%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    --

  • Diluted EPS (ttm)

    -16.51

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    --

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    --

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: